"use strict";(self.webpackChunkbuild_back_better_breakdown=self.webpackChunkbuild_back_better_breakdown||[]).push([[3677],{3905:function(e,t,n){n.d(t,{Zo:function(){return d},kt:function(){return m}});var i=n(7294);function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}function a(e,t){var n=Object.keys(e);if(Object.getOwnPropertySymbols){var i=Object.getOwnPropertySymbols(e);t&&(i=i.filter((function(t){return Object.getOwnPropertyDescriptor(e,t).enumerable}))),n.push.apply(n,i)}return n}function o(e){for(var t=1;t<arguments.length;t++){var n=null!=arguments[t]?arguments[t]:{};t%2?a(Object(n),!0).forEach((function(t){r(e,t,n[t])})):Object.getOwnPropertyDescriptors?Object.defineProperties(e,Object.getOwnPropertyDescriptors(n)):a(Object(n)).forEach((function(t){Object.defineProperty(e,t,Object.getOwnPropertyDescriptor(n,t))}))}return e}function s(e,t){if(null==e)return{};var n,i,r=function(e,t){if(null==e)return{};var n,i,r={},a=Object.keys(e);for(i=0;i<a.length;i++)n=a[i],t.indexOf(n)>=0||(r[n]=e[n]);return r}(e,t);if(Object.getOwnPropertySymbols){var a=Object.getOwnPropertySymbols(e);for(i=0;i<a.length;i++)n=a[i],t.indexOf(n)>=0||Object.prototype.propertyIsEnumerable.call(e,n)&&(r[n]=e[n])}return r}var c=i.createContext({}),l=function(e){var t=i.useContext(c),n=t;return e&&(n="function"==typeof e?e(t):o(o({},t),e)),n},d=function(e){var t=l(e.components);return i.createElement(c.Provider,{value:t},e.children)},u={inlineCode:"code",wrapper:function(e){var t=e.children;return i.createElement(i.Fragment,{},t)}},p=i.forwardRef((function(e,t){var n=e.components,r=e.mdxType,a=e.originalType,c=e.parentName,d=s(e,["components","mdxType","originalType","parentName"]),p=l(n),m=r,b=p["".concat(c,".").concat(m)]||p[m]||u[m]||a;return n?i.createElement(b,o(o({ref:t},d),{},{components:n})):i.createElement(b,o({ref:t},d))}));function m(e,t){var n=arguments,r=t&&t.mdxType;if("string"==typeof e||r){var a=n.length,o=new Array(a);o[0]=p;var s={};for(var c in t)hasOwnProperty.call(t,c)&&(s[c]=t[c]);s.originalType=e,s.mdxType="string"==typeof e?e:r,o[1]=s;for(var l=2;l<a;l++)o[l]=n[l];return i.createElement.apply(null,o)}return i.createElement.apply(null,n)}p.displayName="MDXCreateElement"},3030:function(e,t,n){n.r(t),n.d(t,{frontMatter:function(){return s},contentTitle:function(){return c},metadata:function(){return l},toc:function(){return d},default:function(){return p}});var i=n(7462),r=n(3366),a=(n(7294),n(3905)),o=["components"],s={sidebar_position:2},c="PART 2 - PANDEMIC PREPAREDNESS",l={unversionedId:"title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-2",id:"title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-2",title:"PART 2 - PANDEMIC PREPAREDNESS",description:"SEC. 31021. FUNDING FOR LABORATORY ACTIVITIES AT THE CENTERS FOR",source:"@site/docs/title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-2.md",sourceDirName:"title-3-committee-on-energy-and-commerce/title-3-subtitle-j",slug:"/title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-2",permalink:"/build-back-better-breakdown/docs/title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-2",editUrl:"https://github.com/EdwardAngert/build-back-better-breakdown/tree/main/packages/create-docusaurus/templates/shared/docs/title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-2.md",tags:[],version:"current",sidebarPosition:2,frontMatter:{sidebar_position:2},sidebar:"tutorialSidebar",previous:{title:"PART 1 - HEALTH CARE INFRASTRUCTURE AND WORKFORCE",permalink:"/build-back-better-breakdown/docs/title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-1"},next:{title:"PART 3 - INNOVATION",permalink:"/build-back-better-breakdown/docs/title-3-committee-on-energy-and-commerce/title-3-subtitle-j/title-3-subtitle-j-part-3"}},d=[{value:"SEC. 31021. FUNDING FOR LABORATORY ACTIVITIES AT THE CENTERS FOR",id:"sec-31021-funding-for-laboratory-activities-at-the-centers-for",children:[],level:2}],u={toc:d};function p(e){var t=e.components,n=(0,r.Z)(e,o);return(0,a.kt)("wrapper",(0,i.Z)({},u,n,{components:t,mdxType:"MDXLayout"}),(0,a.kt)("h1",{id:"part-2---pandemic-preparedness"},"PART 2 - PANDEMIC PREPAREDNESS"),(0,a.kt)("h2",{id:"sec-31021-funding-for-laboratory-activities-at-the-centers-for"},"SEC. 31021. FUNDING FOR LABORATORY ACTIVITIES AT THE CENTERS FOR"),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"          DISEASE CONTROL AND PREVENTION.\n\n(a) In General.--In addition to amounts otherwise available, there \n")),(0,a.kt)("p",null,"is appropriated to the Secretary for fiscal year 2022, out of any money\nin the Treasury not otherwise appropriated, $5,000,000,000 for purposes\nof carrying out, acting through the Director of the Centers for Disease\nControl and Prevention (in this section referred to as the\n",(0,a.kt)("inlineCode",{parentName:"p"},"Director''), activities described in subsection (b), to remain \navailable until expended.\n    (b) Use of Funds.--Amounts made available by subsection (a) shall \nbe used for the following activities:\n            (1) Supporting renovation, expansion, and modernization of \n        State and local public health laboratory infrastructure (as the \n        term "),"laboratory'' is defined in section 353 of the Public\nHealth Service Act (42 U.S.C. 263a)), including--\n(A) increasing and enhancing testing and response\ncapacity;\n(B) upgrades and expansion of the Laboratory\nResponse Network for rapid outbreak detection;\n(C) improving and expanding genomic sequencing\ncapabilities to detect emerging diseases and variant\nstrains;\n(D) expanding biosafety and biosecurity capacity;\nand\n(E) making other laboratory enhancements and\nmodernization as determined by the Director to be\nimportant for maintaining public health.\n(2) Renovating, expanding, and modernizing laboratories of\nthe Centers for Disease Control and Prevention as described in\nsubparagraphs (A) through (E) of paragraph (1).\n(3) Enhancing the ability of the Centers for Disease\nControl and Prevention to monitor and exercise oversight over\nbiosafety and biosecurity of State and local public health\nlaboratories."),(0,a.kt)("p",null,"SEC. 31022. FUNDING FOR STRENGTHENING VACCINE CONFIDENCE."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) In General.--In addition to amounts otherwise available, there \n")),(0,a.kt)("p",null,"is appropriated to the Secretary for fiscal year 2022, out of any money\nin the Treasury not otherwise appropriated, $1,250,000,000, to remain\navailable until expended, to carry out, acting through the Director of\nthe Centers for Disease Control and Prevention, directly or by making\ngrants to public or private entities, activities described in\nsubsection (b) in the United States, including its territories and\npossessions.\n(b) Use of Funds.--Amounts made available by subsection (a) shall\nbe used to--\n(1) strengthen vaccine confidence;\n(2) strengthen routinely recommended vaccine programs; and\n(3) improve rates of vaccination, including through\nactivities described in section 313 of the Public Health\nService Act (42 U.S.C. 245)."),(0,a.kt)("p",null,"SEC. 31023. FUNDING FOR SURVEILLANCE ACTIVITIES AT THE CENTERS FOR\nDISEASE CONTROL AND PREVENTION."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) In General.--In addition to amounts otherwise available, there \n")),(0,a.kt)("p",null,"is appropriated to the Secretary for fiscal year 2022, out of any money\nin the Treasury not otherwise appropriated, $1,000,000,000, to remain\navailable until expended, to carry out, acting through the Director of\nthe Centers for Disease Control and Prevention, directly or by making\ngrants to public or private entities, activities described in\nsubsection (b).\n(b) Use of Funds.--Amounts made available by subsection (a) shall\nbe used to--\n(1) enhance and strengthen early warning and detection\nsystems, including public health and health care surveillance,\nwastewater testing, and global and domestic genomic\nsurveillance;\n(2) enhance and strengthen surveillance based in hospitals\nand other health care providers or facilities, and outpatient\nfacility surveillance for severe acute respiratory infection,\ninfluenza-like illness, acute febrile illness, and other\ndiseases as determined by the Director of the Centers for\nDisease Control and Prevention to be in the interest of public\nhealth; and\n(3) strengthen the antibiotic resistance initiative program\nto improve research, stewardship, genomic detection\ncapabilities, and surveillance of existing and emerging\nantimicrobial resistant pathogens."),(0,a.kt)("p",null,"SEC. 31024. FUNDING FOR DATA MODERNIZATION AT THE CENTERS FOR DISEASE\nCONTROL AND PREVENTION."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) In General.--In addition to amounts otherwise available, there \n")),(0,a.kt)("p",null,"is appropriated to the Secretary for fiscal year 2022, out of any money\nin the Treasury not otherwise appropriated, $500,000,000, to remain\navailable until expended--\n(1) to carry out, acting through the Director of the\nCenters for Disease Control and Prevention, directly or by\nmaking grants to public or private entities, activities\ndescribed in subsection (b); and\n(2) to supplement other available funds to carry out\nsimilar data modernization activities authorized by the Public\nHealth Service Act (42 U.S.C. 201 et seq.).\n(b) Use of Funds.--Amounts made available by subsection (a) shall\nbe used for the following:\n(1) Supporting public health data surveillance,\naggregation, and analytics infrastructure modernization\ninitiatives.\n(2) Enhancing reporting and workforce core competencies in\ninformatics and digital health.\n(3) Expanding and maintaining efforts to modernize the\nUnited States disease warning system to forecast and track\nhotspots and emerging biological threats."),(0,a.kt)("p",null,"SEC. 31025. FUNDING FOR PUBLIC HEALTH AND PREPAREDNESS RESEARCH,\nDEVELOPMENT, AND COUNTERMEASURE CAPACITY."),(0,a.kt)("pre",null,(0,a.kt)("code",{parentName:"pre"},"(a) In General.--In addition to amounts otherwise available, there \n")),(0,a.kt)("p",null,"is appropriated to the Secretary for fiscal year 2022, out of any money\nin the Treasury not otherwise appropriated, to remain available until\nexpended, to carry out activities, acting through the Assistant\nSecretary for Preparedness and Response, to prepare for, and respond\nto, public health emergencies declared under section 319 of the Public\nHealth Service Act (42 U.S.C. 247d)--\n(1) $3,000,000,000 to support surge capacity, including\nthrough construction, expansion, or modernization of\nfacilities, to respond to a public health emergency, for\nprocurement and domestic manufacture of drugs, active\npharmaceutical ingredients, vaccines and other biological\nproducts, diagnostic technologies and products, personal\nprotective equipment, medical devices, vials, syringes,\nneedles, and other components or supplies for the Strategic\nNational Stockpile under section 319F-2 of the Public Health\nService Act (42 U.S.C. 247d-6b);\n(2) $2,000,000,000 to support expanded global and domestic\nvaccine production capacity, including by developing or\nacquiring new technology and expanding manufacturing capacity\nthrough construction, expansion, or modernization of\nfacilities;\n(3) $2,000,000,000 to support activities to mitigate supply\nchain risks and enhance supply chain elasticity and resilience\nfor critical drugs, active pharmaceutical ingredients, and\nsupplies (including essential medicines, medical\ncountermeasures, and supplies in shortage or at risk of\nshortage), drug and vaccine raw materials, and other supplies,\nas the Secretary determines appropriate, including\nconstruction, expansion, or modernization of facilities,\nadoption of advanced manufacturing processes, and other\nactivities to support domestic manufacturing of such supplies;\n(4) $500,000,000 to support activities conducted by the\nBiomedical Advanced Research and Development Authority for\nadvanced research, standards development, and domestic\nmanufacturing capacity for drugs, including essential\nmedicines, diagnostics, vaccines, therapeutics, and personal\nprotective equipment; and\n(5) $500,000,000 to support increased biosafety and\nbiosecurity in research on infectious diseases, including by\nmodernization or improvement of facilities."))}p.isMDXComponent=!0}}]);